A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-02-19
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-04-17 (study day 37); relationship: N
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-05-12 (study day 62); relationship: Y
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-07-05 (study day 116); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-10 (study day 274); relationship: N
Data queries
No data queries.